Role of matrix metalloproteinases and their inhibitors in pancreatic cancer

Digestion

Volumn 58, Issue 6, 1997, Pages 520-528

  Evans, James D ^a   Ghaneh, Paula ^a   Kawesha, Anthony ^a   Neoptolemos, John P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Batimastat; Marimastat; Matrix metalloproteinases; Pancreatic cancer; Tissue inhibitors, metalloproteinases

Indexed keywords

BATIMASTAT; CDP 845; CGS 27023A; CIPEMASTAT; COLLAGENASE; CYCLOPHOSPHAMIDE; D 5410; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N1 (1 CARBAMOYL 2,2 DIMETHYLPROPYL) 2 [3 (4 CHLOROPHENYL)PROPYL] N4 HYDROXYBUTANEDIAMIDE; PRINOMASTAT; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAPLEURAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL;

CLINICAL TRIALS; EXTRACELLULAR MATRIX; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTEASE INHIBITORS;

EID: 0030656475     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201495     Document Type: Article

References (106)

1. Goldfarb RH: Proteolytic enzymes in tumour invasion and degradation of host extracellular matrices', in Honn KV, Powers WE, Sloane BF (eds): Mechanisms of Cancer Metastasis, Boston, NijhoIT, 1986, pp 341-375.
2. Liotta LA, Trvggvason K, Garbisa S, Hart I, Foltz CM, Shafdic S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen, Nature 1980:284: 67-68.
3. Charpin C, Lissitzky JC, Jacqucmier J, Lavant MN, Kopp F, Pourrcauschneidcr N, Martin PM, Toga M: Immunohistochemical detection of lantinin in 98 human breast carcinomas: A light and electron microscopic study, Hum Pathol 1986:17:355-365.
4. Forster SJ, Talbot IC, Clayton DG, Critchley DR: Tumour basement membrane laminin in adenocarcinoma of the rectum: An immunohistochemical study of biological and clinical significance, Int J Cancer 1986:37:813-817.
5. Kioppcl G: Pathology of non-endocrine pancreas tumours; in Go LW, DiMagno EP, Gardner HD, Lebenthal E, Reber HA, Scheele GA (eds): The Pancreas: Biology, Pathobiology and Disease, cd 2, New York, Raven Press, 1993, pp 871-897.
6. Lee CS, Montebello J, Gcorgiou T, Rode J: Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis, Int J Exp Pathol 1994:75:79-83.
7. Liotta LA: Tumour invasion and metastasis: Role of the extracellular matrix, Cancer Res 1986:46:1-7.
8. Gotlesman M: The role of protcases in cancer, Semin Cancer Biol 1990; 1:97-100.
9. Ossawski L, Reisch E: Antibodies to plasminogen activator inhibit human tumour metastasis, Cell 1983:35:611-619.
10. Sloane BF, Dunn JR, Huon KV: Lysosomal cathepsin B: Correlation with metastatic potential, Science 1981:212:1 151-1153.
11. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis, Clin Exp Metastasis 1992:10:145-155.
12. Liotta LA, Stetler Stevenson WG: Tumour invasion and metastasis: An imbalance of positive and negative regulation, Cancer Res 1991: 51:5054-5059.
13. Cottam DW, Rees RC: Regulation of matrix metalloproteinases: Their role in tumour invasion and metastasis, Int J Oncol 1993:2:861-872.
14. Délaisse JM, Vacs G: Mechanism of mineral solubilisation and matrix degradation in ocsto-clastic bone resorption: in Rifkin BR, Gay CV (eds): Biology and Physiology of the Osteoclast, Boea Raton, CRC Press, 1992, pp 290-314.
15. Brenner DA, Ohara M, Angel P, Chojkicr M, Karin M: Prolonged activation of jun and colta-gcnasc genes by tumour necrosis factor alpha, Nature 1989:337:661-663.
16. Wolf C, Chenard MP, Durand de Grossouvre P, Bcllocq JP, Chambon P, Basset P: Breast-canccr-associatcd stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing, J Invest Dermatol 1992:99:870-872.
17. Harris E: Rheumatoid arthritis: Pathophysiology and implications for therapy, N Engl J Med 1990:322:1277-1289.
18. Tarin D, Hoyt BJ, Evans DJ: Correlation of collagenase secretion with metastatic colonisation potential in naturally occurring murine mammary tumours, Br J Cancer 1982:46:266-278.
19. Murphy GJP, Murphy G, Reynolds JJ: The origin of matrix metalloproteinases and their familial relationships, FEBS Lett 1991:289:4-7.
20. McCroskery PA, Richards JF, Harris ED: Purification and characterisation of a collagenase extracted from rabbit tumours, Biochem J 1975:152:131-142.
21. Ncthery A, O'Grady RL: Identification of a mctalloproteinase co-purifving with rat tumour collagenase and the characteristics of fragments of both enzymes, Biochim Biophys Acta 1989: 994:149-160.
22. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GL Welgus HG: Human 92-and 72-kilodalton type IV collagcnases are clastases. J Biol Chern 1991:266:7870-7875.
23. Matr sian LM: Metalloproteinases and their inhibitors in matrix remodelling, Trends Genet 1990;6:121-125.
24. Pei D, Majmudar G, Weiss SJ: Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3, J Biol Chem 1994:269:25849-25855.
25. Sato H, Takin T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Sciki M: A matrix mctallopro-tcinase expressed on the surface of invasive tumour cells, Nature 1994;370:61-65.
26. Will H, Hinzman B: cDNA sequence and rnRNA tissue distribution of a novel human matrix mctalloproteinase with a potential transmembranc segment, Eur J Biochem 1995: 231:602-608.
27. Takino T, Sao H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library, J Biol Chem 1995;270:23013-23020.
28. Puente XS, Pendas AM, Llano E, Velasco G, Ldpez-Otin C: Molecular cloning of a novel membrane-type matrix metalloprotcinase form a human breast carcinoma, Cancer Res 1996; 56:944-949.
29. Strongin A, Collier I, Bannikov G, Manner BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72 kDa type IV collagenase, J Biol Chem 1995;270:5331-5338.
30. Quantin B, Murphy G, Brcathnach R: PUMP I cDNA codes for a protein with characteristics similar to those of classical collagenase family members, Biochemistry 1989;28:5325-5334.
31. Shapiro SD, Kobayashi DK, Ley TJ: Cloning and characterisation of a unique elastolytic mc-talloprolcinase produced by human alveolar macrophages, J Biol Chem 1993:268:23824-23829.
32. Cossins J, Dudgeon TJ, Catlin G, Gearing AJI I, Clements JM: Identification of MMP 18, a putative novel human matrix metalloprotei-nasc, Biochem Biophys Res Commun 1996; 228:494-498.
33. Stetler-Stevenson WG: Type IV collagcnascs in tumour invasion and metastasis, Cancer Metastasis Rev 1990:9:289-303.
34. Sanchez-Ldpez R, Alexander CM, Bchrendtscn O, Breathnach R, Werb Z: Role of zinc binding and hemopcxin-domain-encoded sequences in the substrate specificity of collagenase and stromelysin-2 as revealed by chimeric proteins, J Biol Chem 1993:268:7238-7247.
35. Korc M, Chandreskar B, Yamanaka Y, Frciss H, Biichlcr M, Bcger HG: Over-expression of the epidermal growth factor receptor in human pancreatic cancer is associated with coneom-mitant increases in the levels of epidermal growth factor and transforming growth factor alpha, J Clin Invest 1992:90:1352-1360.
36. Shima I, Sasaguri Y, Kasukawa J, Nakano R, Yamana H, Fujita H, Kakegawa T, Morimatsu M: Production of matrix metalloprotcinase 9 (92 kDa gelatinasc) by human oesophageal squamous cell carcinoma in response to epidermal growth factor, Br J Cancer 1993:67:721-727.
37. Sassonc-Corsi P, Lamph WW, Kamps M, Ver-ma IM: Fos-associated cellular p39 is related to nuclear transcription factor AP-I, Cell 1988; 54:553-563.
38. Gutman A, Wasylyk B: The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites, EMBO J 1990:9:2241-2246.
39. Wilhelm SM, Collier IE, Mariner BL, Eisen AZ, Grant GA, Goldberg GL: SV40 transformed human lung fibroblasts secrete a 92 kDa type IV collagenase which is identical to that secreted by normal human macrophages, J Biol Chem 1989:264:17213-17221.
40. Mochan E, Uhl J, Nowlon R: Interleukin I stimulation of synovial cell plasminogen activator production, J Rheumatol 1986:13:15-19.
41. Thorgcirsson UP, Turpeenniemi-Hujanen T, Williams JE, Weshin EH, Heilman CA, Tal-madgc JE, Liotta LA: NIH/3T3 cells transfected with human tumour DNA containing activated ras oncogenes express the metastatic phenotype in nude mice, Mol Cell Biol 1985:5: 259-262.
42. Collier IE, Smith J, Cronenberg A, Bauer EA, Wilhelm SM, Eisen AZ, Goldberg GI: The structure of human skin fibroblast collagenase gene, J Biol Chem 1988:263:10711-10782.
43. Okada Y, Morodomi T, Enghild J, Suzuki K, Yasui A, Nakanishi I, Salvcson G, Nagasc H: Matrix metalloprotcinase 2 from human rheumatoid synovial fibroblasts: Purification and activation of the precursor and enzymic properties, Eur J Biochem 1990:194:721-730.
44. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, iwata K, Yamashita K, Hayakawa T: Matrix metalloprotcinase 9 (92 kDa gelatinasc/ type IV collagenase) from HTI080 human fibrosarcoma cells, J Biol Chem 1992:267: 21712-21719.
45. Okada Y, Tsuchiya H, Shimizu H, Tomita K, Nakanishi I, Sato H, Seiki M, Yamashita K, Hayakawa T: Induction and stimulation of 92 kD gelatinasc/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by-tumour necrosis factor alpha, Biochem Bio-phvsRcsCommun 1990:171:610-617.
46. Pyke C, Kristensen P, Ralfiaer E, Grandahl-hanscn J, Eriksen J, Brasi F, Dano K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells are invasive foci in human colon adenocarcinomas, Am J Pathol 1991:138:1059-1067.
47. He C, Wilhelm SM, Pentland AP, et al: Tissue cooperation in a proteolytic cascade activating human intestinal collagenase, Proc Natl Acad Sci USA 1989:86:2632-2636.
48. Mackey AR, Corbitt RH, Hartzler JL, Thorgeirsson UP: Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases, Cancer Res 1990:50:5997-6001
49. Suzuki K, Enghild JJ, Morodomi T, Salvcson G, Nagase H: Mechanisms of activation of tissue procollagenase by matrix mctalloprolci-nasc3 (stromelysin), Biochemistry 1990:29: 10261-10270.
50. Sang QX, Birkedel-Hanson H, Van Wart LIE: Proteolytic and non-proteolytic activation of human neutrophil progelatinase, Biochim Bio-physActa 1995:1251:99-108.
51. Crabbe T, Smith B, O'connell JP, Dochcrty A: Human procollagenase A can be activated by matrilysin, FEBS Lett 1994;345:14-16.
52. Sellers A, Murphy G, Mcickle MC, Reynolds JJ: Rabbit bone collagenase inhibitor blocks the activity of other neutral metalloproteinases, Biochem Biphys Res Commun 1979:87:581-587.
53. Stetler Stevenson WG: Tissue inhibitor of mc-talloproteinasc (TIMP 2), J Biol Chem 1989; 264:17374-17378.
54. Uria JA, Ferrando AA, Velasco G, Freije JMP, Lopez-Otin C: Structure and expression in breast tumours of human TIMP 3, a new- mem-her of the metalloprotcinase inhibitor family, Cancer Res 1994;54:2091-2094.
55. Greene J, Wang M, I-iu YE, Raymond LA, Rosen C, Chi YE: Molecular cloning and characterisation of human tissue inhibitor of mctal-loproteinase 4, J Biol Cheni 1996:271:30375-30380.
56. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ: Purification of rabbit bone inhibitor of collagenase, Biochem J 1981:195: 159-165.
57. Ponton A, Coulombe B, Skup D: Decreased expression of tissue inhibitor of the mctallopro-teinascs in metastatic tumour cells leading to increased levels of collagenase activity, Cancer Res 1991:51:2138-2143.
58. Dochcrty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR: Sequence of human tissue inhibitor of the metalloprotcinase and its identity to crythroid-potentiating activity, Nature 1985;318:66-69.
59. Mahtani MM, Willard HF: A primary genetic map of the pericentromcric region of the human X chromosome, Genomics 1988:2:294-301.
60. Welgus HG, Stricklin GP: Human skin fibroblast collagenase inhibitor, J Biol Chem 1983; 258:12259-12264.
61. Welgus HG, Jeffrey JJ, Eisen AZ, Roswit WT, Stricklin GP: Human skin fibroblast collage-nasc: Interaction with substrate and inhibitor, Coll Rclat Res 1985:5:167-179.
62. Murphy GJ P, Reynolds JJ, Wcrb Z: Biosynthesis of tissue inhibitor of the metalloproteinases by human fibroblasts in culture, J Biol Chem 1985:260:3079-3083.
63. Hayakawa T, Yamashita K, Tanzawa K, Uchi-jima E, Iwata K: Growth-promoting activity of tissue inhibitor of the metalloproteinases-1 (LIMP I) for a wide range of cells: A possible new growth factor in serum, FEBS Lett 1992; 298:29-32.
64. DcClcrck Y, Yean TD, Ratzkin BJ, Lu HS, Langley KE: Purification and characterisation of two related but distinct metalloprotcinase inhibitors secreted by bovine aortic endothelial cells, J Biol Chem 1989:264:17445-17453.
65. Hewitt RE, Leach IH, Powc DG, Clarke IM, Cawston TE, Turner DR: Distribution of collagenase and tissue inhibitor of the metallopro-tcinases (TIMP) in colorectal tumours, Int J Cancer 1991;49:666-672.
66. Zeng ZS, Guillem JG: Distinct pattern of matrix metalloprotcinase 9 and tissue inhibitor of metalloproteinase I mRNA expression in human colorectal cancer and liver metastasis, Br J Cancer 1995;72:575-582.
67. Grigoni WF, D'Errico A, Fortunato C, Florentine M, Mancini AM, Stetler Stevenson WG, Sober ME, Liotta LA, Onisre M, Garbisa S: Prognosis of gastric carcinoma revealed by interactions between tumour cells and basement membrane, Mod Pathol 1994;7:220-225.
68. Overall CM, Wrana JL, Sodek J: Independent regulation of collagenase, 72 kDa progelati-nase, and mctalloendoprotcinase inhibitor expression in human fibroblasts by transforming growth factor-beta, J Biol Chem 1989:264: 1860-1869.
69. Bramhall SR, Lemoinc N, Stamp G, Neoplole-mos JP: Enhanced expression of matrix metal-loproteinases is often unopposed by their inhibitors (tissue inhibitors of metalloprotci-nases) in pancreatic cancer, Br J Surg 1995:82: 707-708.
70. Van Der Stappcn JWJ, Hendricks T, Wobbes T: Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumours, Int J Cancer 1990:45: 1071-1078.
71. Gallegos NC, Smales C, Savage FJ, Hembry RM, Boulos PB: The distribution of matrix metalloproteinases and tissue inhibitor of the metalloproteinases in colorectal cancer, Surg Oncol 1995;4:21-29.
72. Parsons SL, Watson SA, Collins H, Clarke P, Steele RJC: Colorectal cancers overexpress ge-latinascs (matrix metalloproteinases 2 and 9) (abstract), Gastroenterology 1996:110:574.
73. D'Errico A, Garbisa S, Liolta L, Astronova V, Stetler-Stevenson W, Grigioni W: Augmentation of type IV collagenase, laminin receptor and Ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression, Mod Pathol 1991:4:239-246.
74. Nomura H, Sato H, Seiki M, Mai M, Okada Y: Expression of membrane-type matrix metallo-protcinase in human gastric carcinomas, Cancer Res 1995;55:3263-3266.
75. Campo E, Merino MJ, Tavassoii FA, Charonis AS, Stetler-Stcvenson WG, Liotta LA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serious tumours of the ovary, Am J Surg Pathol 1991:16: 500-507.
76. Pajouh MS, Nagle RB, Brcatynach R, Finch JS, Brawler MK, Bowden GT: Expression of mc-talloproteinasc genes in human prostate cancer, J Cancer Res Clin Oncol 1991; 117:144-150.
77. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limachcr JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloprotei-nase gene specifically expressed in stromal cells of breast carcinomas, Nature 1990:348:699-704.
78. Brown PD, Bloxidge RE, Stuart NSE, Gattcr KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinasc and tumour spread in non-small-cell lung carcinoma, J Natl Cancer Inst 1993:85:574-578.
79. Muller D, Breathnach R, Engclmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecassis J: Expression of collagenase related mctalloprotcinase genes in human lung or head and neck tumours, Int J Cancer 1991:48:550-556.
80. Taniguchi S, Iwamura T, Katsuki T: Correlation between spontaneous metastatic potential and type 1 collagenolytic activity in a human pancreatic cancer cell line (SUIT 2) and sub-lines, Clin Exp Metastasis 1992:10:259-266.
81. Bramhall SR, Lemoine N, Stamp G, Neoptole-mosJP: Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic cancer, J Pathol 1997;182: 347-355.
82. Zucker S, Moll UM, Lysik RM, DiMassimo EL Stetler-Stevenson WG, Liotta LA, Schwcdes JW: Extraction of type-IV collagenase/gelati-nase from plasma membranes of human cancer cells, Int J Cancer 1990:45:1137-1142.
83. Satoh K, Ohtani 11, Shimosegawa T, Koizumi M, Sawai T, Toyota T: Infrequent stromal expression of gelatinasc A and intact basement membrane in intraductal neoplasms of the pancreas, Gastroenterology 1994:107:1488-1495.
84. Gress TM, MUUer-Pillasch F, Lcrch MM, Freiss H, Büchler M, Alder G: Expression and in-situ localisation of genes coding for extracellular matrix proteins and extracellular matrix degrading protcases in pancreatic cancer, Int J Cancer 1995:62:407-413.
85. Bramhall SR, Stamp G, Dunn J, Lemoine N, Neoptolemos JP: Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of metalloproteinases (TIMP1) in pancreatic and ampullary disease, Br J Cancer 1996;73:972-978.
86. Bramhall SR, Lemoinc N, Stamp G, Donovan IA, Dunn J, Neoptolemos JP: 72 kDa collagenase, stromelysin I and tissue inhibitor of me-talloproteinasc I expression in pancreatic cancer, Digestion 1994:55:286.
87. Tsuchiva Y, Satro H, Endo Y, Okada Y, Mai M, Sasaki T, Sciki M: Tissue inhibitor of the metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo, Cancer Res 1993;53:1397-1402.
88. DeClerck Y, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases, Cancer Res 1992;52:701-708.
89. Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Ovasu R: Overexprcssion of tissue inhibitor of the metalloproteinases (TIM P I and TIMP 2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma, Int J Cancer 1995:63:680-687.
90. Davies B, Brown PD, Eats N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloprotci-nasc inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenografts, Cancer Res 1993:53: 2087-2091.
91. Watson SA, Morris TM, Parsons SL, Steele RJC, Brown PB: Therapeutic effect of the matrix metalloproteinase inhibitor batimaslat in a human colorectal cancer ascites model, Br J Cancer 1996;74:1354-1358.
92. Sledge GW, Qualali M, Goulet R, Bone EA, Thomas W, Brown PD: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice, J Natl Cancer Res 1995;87:1546-1550.
93. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice, Cancer Res 1994:54: 4726-4728.
94. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD: Inhibition of organ invasion by the matrix mctallo-proteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastases models, Cancer Res 1995:55:3629-3633.
95. Galardy RE, Grobelnv D, Foellmcr HG, Fernandez LA: Inhibition of angiogcnesis by the matrix metalloproteinase inhibitor N-[2R-2-(hydroxamidocarbonylmethyl)-4-methylpen-tanoyl)]-/.-tryptophan mclhylamide, Cancer Res 1994:54:4715-4718.
96. Taraboloctli G, Garofalo A, Belotti D, Drudis T, Borsoni P, Scanziani E, Brown P, Giavazzi R: Inhibition of angiogencsis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases, J Natl Cancer Inst 1995:87:293-298.
97. Anderson IC, Shipp MA, Docherty AJP, Teicher BA: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma, Cancer Res 1996;56: 715-718.
98. Macualay V, O'Byme K, Saunders M, Salisbury A, Long L, Glcerson F, Gareson TS, Harris AL, Talbot DC: A phase I study of the matrix metalloproteinase inhibitor batimastat (BB-94) in patients with pleural effusions (abstract), Br J Cancer 1995:71:11.
99. Parsons S, Watson S, Amar S, Steele R: Phase I/II trial of a matrix metalloproteinase inhibitor in patients with malignant ascites (abstract), Gastroenterology 1996:110:575.
100. Beckett RP, Davison AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research, Drug Dev Today 1996;1:16-26.
101. Drummond A, Beckett P, Bone EA: BB-2516: An orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models (abstract), Proc Am Assoc Cancer Res 1995:36:100.
102. Parsons SL, Watson SA, Grifin NR, Steele RJC: An open phase 1/11 study of the oral matrix metalloproteinase inhibitor marimas-tat in patients with inoperable gastric cancer (abstract), Ann Oncol 1996:7:47.
103. Primrose J, Bleiberg H, Daniel F, Johnson P, Mansi J, Neoptolemos J, Seymour M, Van Belle S: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer (abstract), Ann Oncol 1996;7:35.
104. Peole C, Adams M, Barley V, Graham J, Kerr D, Louviaux I, Pcrren T, Piccar! M, Thomas H: A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer (abstract), Ann Oncol 1996:7:68.
105. Evans JD, Bramhall SR, Carmichael J, Daniel F, Imric C, Johnson CD, Neoptolemos JP, Stark A: A phase II trial of marimastat (BB-2516) in advanced pancreatic cancer (abstract), Ann Oncol 1996:7:51.
106. Moore M: Activity of gemcitabine in patients with advanced pancreatic cancer, Cancer 1996;78:633-638.